IAM Iambic Therapeutics, Inc.

Fundamentals / CIK 0001997038 / USD

Iambic Therapeutics, Inc. reported $332.1M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open IAM in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for IAM.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2025-09-30
Revenue $11.35M $4.69M
Research & Development $34.10M $23.06M
Total Operating Expenses $41.47M $27.31M
Operating Income -$30.11M -$22.62M
Interest Income $2.00M $1.16M
Interest Expense $3.0K $4.0K
Income Before Tax -$38.51M -$21.46M
Income Tax Expense $0 $0
Net Income -$38.51M -$21.46M
Basic EPS -$8.52 -$5.24
Diluted EPS -$8.52 -$5.24
Basic Shares Outstanding 4.5M 4.1M
Diluted Shares Outstanding 4.5M 4.1M

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for IAM.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2025-12-31
Cash & Cash Equivalents $252.0M $180.5M
Cash & Short-Term Investments $252.0M $180.5M
Accounts Receivable, Net $50.90M $300K
Total Current Assets $315.9M $183.6M
Property, Plant & Equipment, Net $9.03M $4.83M
Other Non-Current Assets $2.11M $1.58M
Total Non-Current Assets $16.16M $11.43M
Total Assets $332.1M $195.0M
Accounts Payable $4.30M $3.32M
Deferred Revenue (Current) $44.79M $11.30M
Other Current Liabilities $5.13M $805K
Total Current Liabilities $74.89M $26.29M
Deferred Revenue (Non-Current) $51.28M $9.08M
Other Non-Current Liabilities $9.0K $91K
Total Non-Current Liabilities $132.3M $13.96M
Total Liabilities $207.2M $40.25M
Total Debt (incl. Leases) $4.89M $5.46M
Common Stock $4.0K $4.0K
Retained Earnings -$283.8M -$195.2M
Accumulated Other Comp. Income $38K $24K
Total Stockholders' Equity -$269.1M -$186.6M
Total Equity -$269.1M -$186.6M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for IAM.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2025-09-30
Net Income -$38.51M -$21.46M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for IAM.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2025-09-30
Current Ratio 4.22x --
Quick Ratio 4.05x --
Revenue Growth (YoY) +141.9% --
Source: SEC EDGAR CompanyFacts (CIK 0001997038) · from September 30, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:47 UTC · Open in terminal